Solvay Loses False Advertising, Trademark Case

Law360, New York (March 6, 2007, 12:00 AM EST) -- KV Pharmaceutical Co. has won a seven-week trial in which Solvay Pharmaceuticals Inc. accused KV and a subsidiary of false advertising.

A federal jury in Minneapolis ruled in favor of KV and its generics subsidiary Ethex on Monday. A spokesman for the plaintiff said Tuesday that Solvay was still evaluating its options.

According to Solvay, Ethex falsely promoted its generic Pangestyme pancreatic enzyme products as bioequivalent versions of Solvay’s branded Creon microspheres.

Solvay accused the defendants of false advertising and unfair and deceptive trade practices....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.